Galantamine versus risperidone for agitation in people with dementia: A randomized, twelve-week, single-center study

Dementia and Geriatric Cognitive Disorders

Volumn 38, Issue 3-4, 2014, Pages 234-244

  Freund Levi, Yvonne ^a,b   Bloniecki, Victor ^a   Auestad, Bjørn ^c,d   Bäckström, Ann Christine Tysen ^b   Lärksäter, Marie ^b   Aarsland, Dag ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF STAVANGER   (Norway)

Author keywords

Agitation; Behavioral and psychologicalsymptoms of dementia; Dementia; Galantamine; Neuropsychiatric symptoms; Risperidone

Indexed keywords

CLOMETHIAZOLE; GALANTAMINE; OXAZEPAM; RISPERIDONE; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

AGED; AGITATION; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; COHEN MANSFIELD AGITATION INVENTORY; CONTROLLED STUDY; DEMENTIA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MILD COGNITIVE IMPAIRMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PARALLEL DESIGN; PERIPHERAL NERVOUS SYSTEM DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIMPSON-ANGUS SCALE; SKIN DISEASE; TREATMENT DURATION; URINARY TRACT DISEASE; ADULT; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; GASTROINTESTINAL TOXICITY; MINI MENTAL STATE EXAMINATION; SKIN TOXICITY; ALZHEIMER DISEASE; COMPARATIVE STUDY; DEMENTIA, VASCULAR; PSYCHOLOGY; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DEMENTIA; DEMENTIA, VASCULAR; FEMALE; GALANTAMINE; HUMANS; MALE; NOOTROPIC AGENTS; PSYCHOMOTOR AGITATION; RISPERIDONE; TREATMENT OUTCOME;

EID: 84902912373     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000362204     Document Type: Article

References (37)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708-714.
2. Morley JE: Dementia-related agitation. J Am Med Dir Assoc 2011; 12: 611-612.
3. Selbaek G, Kirkevold O, Engedal K: The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22: 843-849.
4. Allegri RF, Sarasola D, Serrano CM, Taragano FE, Arizaga RL, Butman J, Loñ L: Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease. Neuropsychiatr Dis Treat 2006; 2: 105-110.
5. Schnaider Beeri M, Werner P, Davidson M, Noy S: The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002; 17: 403-408.
6. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT: Determinants of quality of life in nursing home residents with dementia. Dement Geriatr Cogn Disord 2010; 29: 189-197.
7. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB: Behavioral and psychological symptoms of dementia. Front Neurol 2012; 3: 73.
8. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG: Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5: 245-255.
9. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-143.
10. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: metaanalysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191-210.
11. Profenno LA, Tariot PN: Pharmacologic management of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 65-77.
12. Maher A, Maglione M, Bagley S, et al: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306: 1359-1369.
13. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group: Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165: 844-854.
14. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168: 831-883.
15. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596-608.
16. Rodda J, Morgan S, Walker Z: Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebocontrolled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009; 21: 813-824.
17. Trinh N, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210-216.
18. Herrmann N, Rabheru K, Wang J, Binder C: Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005; 13: 527-534.
19. O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED: Nicotinic α 4 β 2 - receptor binding in dementia with Lewy bodies using 123I-5IA 85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage 2008; 40: 1056-1063.
20. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M; CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-1392.
21. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacob R: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330: 874.
22. Freund-Levi Y, Jedenius E, Tysen-Bäckström AN, Lärksäter M, Wahlund LO, Eriksdotter M: Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am J Geriatr Psychiatry 2014; 22: 341-348.
23. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
24. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc 1986; 34: 711-721.
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1995.
26. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
27. Zuidema SU, Buursema AL, Gerritsen MG, Oosterwal KC, Smits MM, Koopmans RT, de Jonghe JF: Assessing neuropsychiatric symptoms in nursing home patients with dementia: reliability and Reliable Change Index of the Neuropsychiatric Inventory and the Cohen-Mansfield Agitation Inventory. Int J Geriatr Psychiatry 2011; 26: 127-134.
28. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
29. Ballard CG, Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD003476.
30. Carson S, McDonagh MS, Peterson K: A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 2006; 54: 354-361.
31. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita Gunawardena ND, Hogg F, Clare C, Damms J: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214-219.
32. Holmes C, Wilkinson D, Dean C, Clare C, El-Okl M, Hensford C, Moghul S: Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. Int J Geriatr Psychiatry 2007; 22: 380-381.
33. Wilcock GK, Ballard CG, Cooper JA, Loft H: Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69: 341-348.
34. Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M: Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23: 161-169.
35. Rösler M, Retz W, Retz-Junginger P, Dennle H-J: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998; 4: 211-216.
36. Cummings JL, Koumaras B, Chen M, Mirski D; Rivastigmine Nursing Home Study Team: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3: 137-148.
37. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-115.